We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

25 hedge funds and large institutions have $36.2M invested in Aldeyra Therapeutics in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 4

99% more capital invested

Capital invested by funds: $18.2M → $36.2M (+$18M)

11% less funds holding

Funds holding: 2825 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
25
Holders Change
-3
Holders Change %
-10.71%
% of All Funds
0.67%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
14
Reduced
4
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SM
26
Sabby Management
Florida
-$172K -41,096 Closed
UBS Group
27
UBS Group
Switzerland
-$12K -2,784 Closed
VIA
28
Vantage Investment Advisors
Pennsylvania
-$8K -2,000 Closed
TRCT
29
Tower Research Capital (TRC)
New York
-$3K -636 Closed

ALDX Hedge Fund Activity: Q2 2016 in Review

25 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2016, worth a combined $36.2M — up 99% from $18.2M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ALDX and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 14 added.

The largest buyer was AWM Investment Company, opening a new position worth an estimated $5.13M. The largest seller was Deerfield Management, cutting an estimated $1.14M.

  • 25 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2016, down from 28 in Q1 2016.
  • Funds reported $36.2M of Aldeyra Therapeutics stock for Q2 2016, up 99% quarter-over-quarter.
  • 2 funds opened new Aldeyra Therapeutics positions in Q2 2016 and 5 closed out, a net change of -3 holders.
  • The largest Aldeyra Therapeutics buyer in Q2 2016 was AWM Investment Company, an estimated $5.13M added.
  • The largest Aldeyra Therapeutics seller in Q2 2016 was Deerfield Management, an estimated $1.14M sold.

Based on aggregated 13F filings for Q2 2016.